Peptide Therapeutics Market Size 2024-2028: Insights and Trends

The peptide therapeutics market is poised for significant growth, with a forecasted increase of USD 17.85 billion at a CAGR of 10.03% from 2023 to 2028. This growth is driven by the rising prevalence of chronic diseases and the demand for innovative treatment options. As a major segment of the pharmaceutical industry, peptide therapeutics are gaining traction for their ability to target diseases like cancer, metabolic disorders, and osteoarthritis with minimal toxicity. However, the market faces challenges such as complex manufacturing processes, high costs, and distribution hurdles.

For more details about the industry, get the PDF sample report for free

Market Segmentation and Forecast

The peptide therapeutics market is segmented based on the route of administration and geography, with detailed analysis and forecasts for the period 2024-2028. Key segments and their insights include:

Route of Administration:

1. Parenteral
2. Oral
3. Others

Parenteral administration is anticipated to witness substantial growth during the forecast period. While the oral route faces challenges due to instability in the gastrointestinal tract, the parenteral route, particularly injectable peptide therapeutics, continues to be the dominant method of administration.

Geography

• North America
  • Canada
  • US
• Europe
  • Germany
  • UK
• Asia
  • China
• Rest of World (ROW)

Market Dynamics: Drivers, Trends, and Challenges

Drivers:

• Increasing Prevalence of Infectious Diseases: Peptide therapeutics are gaining prominence due to their potential in managing infectious diseases, along with chronic conditions like cancer, diabetes, and obesity.
• FDA Approvals: The approval of peptide-based drugs like Adlyxin, Ozempic, and Xultophy in the metabolic segment, especially for Type 2 diabetes, is propelling market growth.

Trends:

• Collaborations for R&D: The increasing number of partnerships between industry players and research institutions is enhancing R&D efforts in peptide therapeutics.
• Innovative Delivery Systems: The adoption of oral peptide delivery systems and peptide-based vaccines are shaping market growth, overcoming the challenges associated with peptide stability and administration.

Get more details by ordering the complete report

Challenges:

• Manufacturing Complexities: The complex process of synthesizing peptides through solid-phase reactors and resins, along with high purification costs, remains a key challenge.
• High Costs: The expensive manufacturing equipment and the insolubility issues associated with long peptides present significant barriers to cost-effective production.

Key Players in the Peptide Therapeutics Market:

1. Almac Group Ltd.
2. AmbioPharm Inc.
3. Amgen Inc.
4. AstraZeneca Plc
5. Bachem AG
6. Bristol Myers Squibb Co.
7. Corden Pharma International GmbH
8. Eli Lilly and Co.
9. Ever Pharma
10. F. Hoffmann La Roche Ltd.
11. GlaxoSmithKline Plc
12. Ipsen Pharma
13. Lonza Group Ltd.
14. Novartis AG
15. Novo Nordisk AS
16. PeptiDream Inc.
17. Pfizer Inc.
18. PolyPeptide Group
19. Sanofi SA
20. Takeda Pharmaceutical Co. Ltd.
21. Teva Pharmaceutical Industries Ltd.
22. Worg pharma

Future Market Insights:

The peptide therapeutics market is expected to continue its growth trajectory, driven by increasing collaboration in R&D, advancements in peptide synthesis, and the growing need for effective treatments for chronic diseases. Emerging technologies in peptide drug delivery systems, along with regulatory support for peptide-based therapeutics, will pave the way for more innovative solutions in the coming years.